Youssef Hafez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Youssef Hafez has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Wing-Kin Syn
Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Louis University School of Medicine , Saint Louis, MO
2 shared publications - Aasma Shaukat
Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA
1 shared publication Adam D. Farmer
Affiliations Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America, Department of Pathology, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America
1 shared publication- Ahmad Basil Nasir
Affiliation Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America
1 shared publication - Ahmed Salem
Division of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, FL 33331, USA
1 shared publication - Ali Osman
Department of Internal Medicine, Washington University School of Medicine , St. Louis, MO
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (4)
Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis
Background: Inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) frequently coexist and share overlapping immune pathways, yet comparative real-world outcomes between IL-12/23 or IL-23 inhibitors and Janus kinase (JAK) inhibitors in this population remain poorly defined. Methods: We conducted a retrospective cohort study using a large, multicenter, real-world dataset. Adults (≥16 years) with IBD and HS who initiated an IL-12/23 or IL-23 inhibitor after anti-TNF therapy or a JAK inhibitor were included; patients with prior exposure to the opposing drug class were excluded. Propensity score matching (1:1) yielded 150 patients per cohort. Outcomes from 30-365 days included acute care utilization, corticosteroid use, IBD complications, and overall and hidradenitis-specific antibiotic use. Results: After propensity score matching, 300 patients were included (150 per cohort; mean age 38 years; 75.3% female). Rates of emergency department visits or hospitalization were similar between groups (RR 1.20, 95% CI, 0.82-1.77). Corticosteroid use risk was numerically higher in the IL-12/23 or IL-23 cohort (RR 1.20, 95% CI, 0.98-1.46). IBD-related complications did not differ significantly (RR 1.06, 95% CI, 0.58-1.93). Overall antibiotic use was comparable, while hidradenitis-specific antibiotic use was higher in the IL-12/23 or IL-23 cohort (RR 1.47, 95% CI, 1.11-1.95). Conclusions: In this real-world analysis, IL-12/23 or IL-23 inhibitor therapy was associated with higher hidradenitis-specific antibiotic use and numerically greater but statistically nonsignificant corticosteroid exposure, while hospitalization and IBD-related complications were comparable. These findings should be interpreted cautiously given the absence of validated disease-activity measures; prospective studies are needed to inform optimal therapeutic selection.
- 5 October 2026
- Published by Oxford University Press (OUP) in Crohn’s & Colitis 360
- Vol. 8 (4)
Open AccessComparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis
Background: Inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) frequently coexist and share overlapping immune pathways, yet comparative real-world outcomes between IL-12/23 or IL-23 inhibitors and Janus kinase (JAK) inhibitors in this population remain poorly defined. Methods: We conducted a retrospective cohort study using a large, multicenter, real-world dataset. Adults (≥16 years) with IBD and HS who initiated an IL-12/23 or IL-23 inhibitor after anti-TNF therapy or a JAK inhibitor were included; patients with prior exposure to the opposing drug class were excluded. Propensity score matching (1:1) yielded 150 patients per cohort. Outcomes from 30-365 days included acute care utilization, corticosteroid use, IBD complications, and overall and hidradenitis-specific antibiotic use. Results: After propensity score matching, 300 patients were included (150 per cohort; mean age 38 years; 75.3% female). Rates of emergency department visits or hospitalization were similar between groups (RR 1.20, 95% CI, 0.82-1.77). Corticosteroid use risk was numerically higher in the IL-12/23 or IL-23 cohort (RR 1.20, 95% CI, 0.98-1.46). IBD-related complications did not differ significantly (RR 1.06, 95% CI, 0.58-1.93). Overall antibiotic use was comparable, while hidradenitis-specific antibiotic use was higher in the IL-12/23 or IL-23 cohort (RR 1.47, 95% CI, 1.11-1.95). Conclusions: In this real-world analysis, IL-12/23 or IL-23 inhibitor therapy was associated with higher hidradenitis-specific antibiotic use and numerically greater but statistically nonsignificant corticosteroid exposure, while hospitalization and IBD-related complications were comparable. These findings should be interpreted cautiously given the absence of validated disease-activity measures; prospective studies are needed to inform optimal therapeutic selection.
- Open Access
- 21 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Medication Use and Risk of Microscopic Colitis: A Propensity‐Matched Analysis of US Adults ≥ 50 Years (2014–2024)
Background: The association between medications—including non‐steroidal anti‐inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs) and selective serotonin reuptake inhibitors (SSRIs)—and microscopic colitis (MC) remains controversial. While earlier studies suggested increased risk, more recent analyses have challenged these findings, citing methodological limitations. We evaluated the risk of MC among commonly implicated medications using a large national U.S. database. Methods: Using the TriNetX database (2014–2024), we conducted a retrospective cohort study including adults ≥ 50 years with at least one documented healthcare encounter and no prior MC or inflammatory bowel disease. Exposure was defined as ≥ 3 prescriptions within a drug class. Treatment groups (NSAIDs, PPIs, SSRIs, ACE inhibitors [ACEIs], angiotensin receptor blockers [ARBs], statins) were 1:1 propensity score‐matched (PSM) to untreated controls on age, sex, race, comorbidities and previous colonoscopy. The primary outcome was incident MC, identified by new diagnostic codes. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Results: After PSM, cohorts included 907,266 NSAID, 750,009 PPI, 308,310 SSRI, 393,952 ACEI, 298,480 ARB users and 548,339 statin users. Over 2 years, MC risk was increased with NSAIDs (HR 1.15; 95% CI, 1.02–1.30), PPIs (HR 1.36; 95% CI, 1.19–1.54) and SSRIs (HR 1.52; 95% CI, 1.27–1.83). ACEIs, ARBs and statins were not associated with MC. Conclusions: In this large cohort, NSAIDs, PPIs and SSRIs were associated with an increased risk of MC, whereas no significant association was observed for ACEIs, ARBs or statins. Medication review should be considered in patients with new‐onset chronic diarrhoea.
- 21 September 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessMedication Use and Risk of Microscopic Colitis: A Propensity‐Matched Analysis of US Adults ≥ 50 Years (2014–2024)
Background: The association between medications—including non‐steroidal anti‐inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs) and selective serotonin reuptake inhibitors (SSRIs)—and microscopic colitis (MC) remains controversial. While earlier studies suggested increased risk, more recent analyses have challenged these findings, citing methodological limitations. We evaluated the risk of MC among commonly implicated medications using a large national U.S. database. Methods: Using the TriNetX database (2014–2024), we conducted a retrospective cohort study including adults ≥ 50 years with at least one documented healthcare encounter and no prior MC or inflammatory bowel disease. Exposure was defined as ≥ 3 prescriptions within a drug class. Treatment groups (NSAIDs, PPIs, SSRIs, ACE inhibitors [ACEIs], angiotensin receptor blockers [ARBs], statins) were 1:1 propensity score‐matched (PSM) to untreated controls on age, sex, race, comorbidities and previous colonoscopy. The primary outcome was incident MC, identified by new diagnostic codes. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Results: After PSM, cohorts included 907,266 NSAID, 750,009 PPI, 308,310 SSRI, 393,952 ACEI, 298,480 ARB users and 548,339 statin users. Over 2 years, MC risk was increased with NSAIDs (HR 1.15; 95% CI, 1.02–1.30), PPIs (HR 1.36; 95% CI, 1.19–1.54) and SSRIs (HR 1.52; 95% CI, 1.27–1.83). ACEIs, ARBs and statins were not associated with MC. Conclusions: In this large cohort, NSAIDs, PPIs and SSRIs were associated with an increased risk of MC, whereas no significant association was observed for ACEIs, ARBs or statins. Medication review should be considered in patients with new‐onset chronic diarrhoea.
- Open Access
- 9 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0353160
Metabolic risk and metabolic dysfunction–associated steatotic liver disease and steatohepatitis in cognitive decline: A retrospective cohort study
Objective: To determine whether metabolic risk factors (MRFs), metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are associated with incident mild cognitive impairment (MCI), vascular dementia (VD), and Alzheimer disease (AD). Design: Retrospective cohort study using TriNetX (2003–2023) with Propensity score matching. Setting: Multicenter, population-based sample from 69 U.S. healthcare organizations in the TriNetX electronic health record. Participants: Adults aged ≥50 years with ≥1 outpatient visit and sufficient clinical/laboratory data. Individuals with prior diagnoses of cognitive impairment, cerebrovascular disease, advanced liver disease, malignancy, schizophrenia, or substance use disorders were excluded. Two matched cohorts were constructed: one with 3,546,833 individuals with MRFs and 3,546,833 healthy controls, and another with 525,844 individuals with MASLD/MASH and 525,844 with MRFs only. Matching was based on age, sex, race, and ethnicity. Primary and secondary outcome measures: Incident MCI, VD, and AD, identified using ICD-10 codes, assessed at 5–20-year intervals. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression. Outcomes were prespecified. Results: Among 7,818,146 participants (mean [SD] age, 64.9 [8.8] years; 52.0% female), individuals with MRFs had higher odds of VD (OR, 1.65; 95% CI, 1.63–1.67), MCI (OR, 1.45; 95% CI, 1.42–1.48), and AD (OR, 1.21; 95% CI, 1.19–1.24) vs healthy controls. Compared to the MRF group, individuals with MASLD/MASH had lower odds of VD (OR, 0.86; 95% CI, 0.83–0.89) and AD (OR, 0.83; 95% CI, 0.78–0.88), but higher odds of MCI (OR, 1.37; 95% CI, 1.30–1.44); all p < .001. Conclusions: In this large, propensity-matched retrospective cohort study, MRFs were independently associated with significantly increased long-term odds of MCI, VD, and AD. MASLD/MASH demonstrated a divergent cognitive risk profile relative to MRFs alone—characterized by higher odds of MCI but paradoxically lower odds of VD and AD, a pattern that warrants cautious interpretation given potential competing mortality risk, survivor bias, and residual confounding. These findings suggest that MASLD/MASH is associated with a distinct cognitive trajectory, highlighting the importance of early cognitive surveillance in this population.
- 9 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0353160
Open AccessMetabolic risk and metabolic dysfunction–associated steatotic liver disease and steatohepatitis in cognitive decline: A retrospective cohort study
Objective: To determine whether metabolic risk factors (MRFs), metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are associated with incident mild cognitive impairment (MCI), vascular dementia (VD), and Alzheimer disease (AD). Design: Retrospective cohort study using TriNetX (2003–2023) with Propensity score matching. Setting: Multicenter, population-based sample from 69 U.S. healthcare organizations in the TriNetX electronic health record. Participants: Adults aged ≥50 years with ≥1 outpatient visit and sufficient clinical/laboratory data. Individuals with prior diagnoses of cognitive impairment, cerebrovascular disease, advanced liver disease, malignancy, schizophrenia, or substance use disorders were excluded. Two matched cohorts were constructed: one with 3,546,833 individuals with MRFs and 3,546,833 healthy controls, and another with 525,844 individuals with MASLD/MASH and 525,844 with MRFs only. Matching was based on age, sex, race, and ethnicity. Primary and secondary outcome measures: Incident MCI, VD, and AD, identified using ICD-10 codes, assessed at 5–20-year intervals. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression. Outcomes were prespecified. Results: Among 7,818,146 participants (mean [SD] age, 64.9 [8.8] years; 52.0% female), individuals with MRFs had higher odds of VD (OR, 1.65; 95% CI, 1.63–1.67), MCI (OR, 1.45; 95% CI, 1.42–1.48), and AD (OR, 1.21; 95% CI, 1.19–1.24) vs healthy controls. Compared to the MRF group, individuals with MASLD/MASH had lower odds of VD (OR, 0.86; 95% CI, 0.83–0.89) and AD (OR, 0.83; 95% CI, 0.78–0.88), but higher odds of MCI (OR, 1.37; 95% CI, 1.30–1.44); all p < .001. Conclusions: In this large, propensity-matched retrospective cohort study, MRFs were independently associated with significantly increased long-term odds of MCI, VD, and AD. MASLD/MASH demonstrated a divergent cognitive risk profile relative to MRFs alone—characterized by higher odds of MCI but paradoxically lower odds of VD and AD, a pattern that warrants cautious interpretation given potential competing mortality risk, survivor bias, and residual confounding. These findings suggest that MASLD/MASH is associated with a distinct cognitive trajectory, highlighting the importance of early cognitive surveillance in this population.
- Open Access
Metabolic and Laboratory Biomarkers in Early-Onset Versus Late-Onset Colorectal Cancer: A Case–Control Study
Background: The incidence of early-onset colorectal cancer (EOCRC) is rising, yet the relative contribution of metabolic, inflammatory, and laboratory abnormalities remains incompletely defined. Objectives: We compared these associations between EOCRC and late-onset colorectal cancer (LOCRC) while addressing the possibility that some laboratory abnormalities may reflect occult cancer rather than antecedent risk. Methods: We conducted a matched case–control study using the TriNetX US Network. Adults diagnosed with CRC between 2010 and 2023 were identified as EOCRC (18–49 years) or LOCRC (50–75 years). Patients with prior malignancy, inflammatory bowel disease, hereditary or familial CRC risk, or prior colectomy were excluded. Three separate analyses were performed. First, a direct EOCRC-versus-LOCRC comparison evaluated gastrointestinal symptoms during the 6 months preceding diagnosis. Second, EOCRC and LOCRC were each compared with their respective matched cancer-free controls to assess clinical, metabolic, and laboratory features during the 24 months preceding diagnosis. When multiple laboratory values were available, the most recent value preceding the index date was used. Conditional logistic regression estimated adjusted odds ratios with 95% confidence intervals, with Bonferroni correction applied for multiple comparisons. Results: The direct matched EOCRC-versus-LOCRC comparison included 7752 patients with CRC, comprising 2584 with EOCRC and 5168 with LOCRC. EOCRC more frequently presented with rectal bleeding, abdominal pain, diarrhea, iron-deficiency anemia, and weight loss. Rectal tumors were more common in EOCRC, whereas proximal tumors were more common in LOCRC. In separate control-based analyses, 3217 patients with EOCRC and 12,112 patients with LOCRC were compared with 6434 and 24,336 matched cancer-free controls, respectively. The strongest independent features associated with EOCRC were severe obesity (aOR 2.61), microcytosis (aOR 2.29), low ferritin (aOR 2.11), and elevated C-reactive protein (aOR 1.87). Similar but generally attenuated associations were observed in LOCRC. In adjusted EOCRC-versus-LOCRC analyses, obesity (aOR 1.38), metabolic syndrome (aOR 1.41), and MASH (aOR 1.22) remained more closely associated with EOCRC. Conclusions: EOCRC is associated with a distinct clinical–metabolic phenotype, with more pronounced metabolic, inflammatory, and hematologic abnormalities than LOCRC. These findings should be interpreted as hypothesis-generating prediagnostic associations, not as validated predictors or causal risk factors.
Open AccessMetabolic and Laboratory Biomarkers in Early-Onset Versus Late-Onset Colorectal Cancer: A Case–Control Study
Background: The incidence of early-onset colorectal cancer (EOCRC) is rising, yet the relative contribution of metabolic, inflammatory, and laboratory abnormalities remains incompletely defined. Objectives: We compared these associations between EOCRC and late-onset colorectal cancer (LOCRC) while addressing the possibility that some laboratory abnormalities may reflect occult cancer rather than antecedent risk. Methods: We conducted a matched case–control study using the TriNetX US Network. Adults diagnosed with CRC between 2010 and 2023 were identified as EOCRC (18–49 years) or LOCRC (50–75 years). Patients with prior malignancy, inflammatory bowel disease, hereditary or familial CRC risk, or prior colectomy were excluded. Three separate analyses were performed. First, a direct EOCRC-versus-LOCRC comparison evaluated gastrointestinal symptoms during the 6 months preceding diagnosis. Second, EOCRC and LOCRC were each compared with their respective matched cancer-free controls to assess clinical, metabolic, and laboratory features during the 24 months preceding diagnosis. When multiple laboratory values were available, the most recent value preceding the index date was used. Conditional logistic regression estimated adjusted odds ratios with 95% confidence intervals, with Bonferroni correction applied for multiple comparisons. Results: The direct matched EOCRC-versus-LOCRC comparison included 7752 patients with CRC, comprising 2584 with EOCRC and 5168 with LOCRC. EOCRC more frequently presented with rectal bleeding, abdominal pain, diarrhea, iron-deficiency anemia, and weight loss. Rectal tumors were more common in EOCRC, whereas proximal tumors were more common in LOCRC. In separate control-based analyses, 3217 patients with EOCRC and 12,112 patients with LOCRC were compared with 6434 and 24,336 matched cancer-free controls, respectively. The strongest independent features associated with EOCRC were severe obesity (aOR 2.61), microcytosis (aOR 2.29), low ferritin (aOR 2.11), and elevated C-reactive protein (aOR 1.87). Similar but generally attenuated associations were observed in LOCRC. In adjusted EOCRC-versus-LOCRC analyses, obesity (aOR 1.38), metabolic syndrome (aOR 1.41), and MASH (aOR 1.22) remained more closely associated with EOCRC. Conclusions: EOCRC is associated with a distinct clinical–metabolic phenotype, with more pronounced metabolic, inflammatory, and hematologic abnormalities than LOCRC. These findings should be interpreted as hypothesis-generating prediagnostic associations, not as validated predictors or causal risk factors.